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Adaptive Foxp3+CD4+ regulatory T (iTreg) cells develop outside the thymus under subimmunogenic antigen
presentation, during chronic inflammation, and during normal homeostasis of the gut. iTreg cells are essential
in mucosal immune tolerance and in the control of severe chronic allergic inflammation, and most likely are
one of the main barriers to the eradication of tumors. The Foxp3+ iTreg cell repertoire is drawn from naive
conventional CD4+ T cells, whereas natural Treg (nTreg) cells are selected by high-avidity interactions in
the thymus. The full extent of differences and similarities between iTreg and nTreg cells is yet to be defined.
We speculate that iTreg cell development is driven by the need tomaintain a noninflammatory environment in
the gut, to suppress immune responses to environmental and food allergens, and to decrease chronic inflam-
mation, whereas nTreg cells prevent autoimmunity and raise the activation threshold for all immune
responses.Introduction
The transcription factor Foxp3 is essential to establish a func-
tional regulatory T (Treg) cell lineage (Fontenot et al., 2003;
Hori et al., 2003; Khattri et al., 2003; Sakaguchi et al., 2008;
Zheng and Rudensky, 2007). Throughout this review, we will
use the nomenclature ‘‘natural Treg (nTreg) cells’’ for thymic-
derived Foxp3+ Treg cells and ‘‘adaptive Treg (iTreg) cells’’ for
peripherally generated Foxp3+ T cells. Foxp3 iTreg cells such
as Tr1 and Th3 cells will not be discussed.
Numerous studies have proposed and demonstrated that
nTreg cells are generated in the thymus through MHC class II-
dependent T cell receptor (TCR) interactions resulting in high-
avidity selection (Apostolou et al., 2002; Bensinger et al., 2001;
Fontenot et al., 2005b; Jordan et al., 2001; Larkin et al., 2008;
Modigliani et al., 1996; Sakaguchi, 2001), although additional
selection mechanisms may take place (van Santen et al.,
2004). In recent years it became evident that Foxp3+ Treg cells
could also be generated outside the thymus under a variety of
conditions (Figure 1). In this review we will discuss the current
knowledge of adaptive iTreg generation and function, the areas
that need further development to understand and distinguish
iTreg cells and nTreg cells, and the proposed specific roles of
nTreg cells and iTreg cells on tolerance and inflammation.
Differentiation of Foxp3+ Regulatory T Cells outside
the Thymus
A comparison between IL-2-deficient Treg cells (which are
CD25 negative, but, surprisingly, effective at preventing autoim-
mune disease) with CD25-deficient T cells (which, in contrast to
IL-2-deficient cells, are ineffective suppressors) led us to
propose a model whereby acquisition of CD25 expression in
cells that were previously CD25 negative was a requisite for
the functionality of Treg cells (Furtado et al., 2002). Thus,
CD25-negative cells from IL-2-deficient mice converted to
CD25 positive in the presence of IL-2 produced by effector
T cells, and, in the process, gained Treg cell function. Impor-626 Immunity 30, May 22, 2009 ª2009 Elsevier Inc.tantly, when the key role of Foxp3 in Treg cell biology was
demonstrated, nonregulatory T cells were shown to be able to
acquire Foxp3 expression and regulatory function (Apostolou
and von Boehmer, 2004; Cobbold et al., 2004; Curotto de La-
faille et al., 2004).
Some of the early evidence of peripheral conversion of naive
conventional CD4+ cells into Foxp3+ T cells originated from adop-
tive transfer experiments in which polyclonal CD4+CD25 naive
T cells were injected into lymphopenic mice or mice containing
a monoclonal T cell repertoire devoid of nTreg cells (Curotto de
Lafaille et al., 2004; Furtado et al., 2002). In such conditions, in
which homeostatic proliferation of the donor lymphocytes took
place, part of the donor population became CD25+CTLA-
4+GITR+ and acquired Foxp3 expression and suppressive
activity. Given the experimental design, it is possible that these
CD25+Foxp3+ Treg cells originated from CD25Foxp3+ cells
present in the initial population. This is not the case when TCR
transgenic Foxp3+ T cells were generated, because kinetic and
other considerations indicate that they are derived from Foxp3
cells. In addition, Knoechel et al. (2005) studied the conversion
of naive T cells into Foxp3+ Treg cells during peripheral expansion
by using an experimental system in which antigen-specific naive
CD4+ T cells were transferred into lymphocyte-deficient RAG-
deficient mice that expressed the antigen as a systemic secreted
protein. Under these conditions, massive T cell activation re-
sulted in acute graft versus host (GvH)-like disease followed by
a recovery phase associated with de novo generation of Treg
cells. iTreg cell generation did not require the thymus but was
dependent on IL-2.
iTreg cell induction by foreign antigens has been described by
several groups. von Boehmer and colleagues showed the gener-
ation of Foxp3+ iTreg cells in mice treated with minute antigen
doses by osmotic pump delivery (Apostolou and von Boehmer,
2004), and after delivery of antigen crosslinked to DEC-205 anti-
body in the absence of costimulatory signals, a process that
directs the antigen to DEC-205+ dendritic cells (Kretschmer
Immunity
Reviewet al., 2005). By utilizing a similar principle, Waldmann and
coworkers described the conversion of transplant-specific naive
CD4+ T cells into Foxp3+ Treg cells in mice made tolerant by
treatment with nondepleting CD4 antibodies (Cobbold et al.,
2004). Our laboratory showed that ovalbumin (OVA)-specific
Foxp3+ Treg cells appeared in mesenteric lymph nodes (LNs)
of mice administered the antigen chicken ovalbumin by oral
route, a treatment that induces oral tolerance (Mucida et al.,
2005). The use of the mucosal delivery of antigen, in particular
the oral route, as a mean to generate Foxp3+ iTreg cells has
now become a major method of iTreg cell generation in vivo
because of its simplicity, the effectiveness of these Treg cells
in vitro and in vivo assays, and the fact that concomitant effector
T cell generation is inefficient. Interestingly, we also showed that
OVA-specific Treg cells were induced, alongside a much larger
number of T helper 2 (Th2) cells, in spleens and LNs of naive
mice after intraperitoneal immunization with OVA in the adjuvant
alum (Mucida et al., 2005).
Protocols have been developed to differentiate Foxp3+ Treg
cells in vitro from naive conventional T cells in culture settings,
particularly after the description that TGF-b induces Foxp3
expression in TCR-activated naive CD4 cells (Chen et al.,
2003; Fantini et al., 2004). Thus, it is clear that naive CD4+
T cells selected as Foxp3 in the thymus have full potential to
become Foxp3+ Treg cells in vivo and in vitro.
Mechanisms of iTreg Cell Differentiation:
TGF-b, IL-2, and Costimulation
Although nTreg cells develop in a highly controlled thymic micro-
environment (Josefowicz and Rudensky, 2009, in this issue of
Figure 1. Thymic and Peripheral Generation of Foxp3+ Treg Cells
Natural Treg (nTreg) cells differentiate in the thymus and migrate to peripheral
tissues. Adaptive Foxp3+ Treg (iTreg) cells differentiate in secondary lymphoid
organs and tissues. The peripheral population of Foxp3+ Treg cells comprises
both nTreg and iTreg cells. It is very likely that nTreg and Foxp3+ iTreg cells
differ in their TCR repertoire because iTreg cells are derived from mature
peripheral naive CD4+ cells.Immunity), Foxp3+ iTreg cells differentiate under more varied
conditions (Box 1). For example, iTreg cells appear in the
mesenteric LNs during induction of oral tolerance (Coombes
et al., 2007; Mucida et al., 2005), they may continuously differen-
tiate in the lamina propria of the gut in response to microbiota
and food antigens (Sun et al., 2007); they are also generated in
chronically inflamed tissues (Curotto de Lafaille et al., 2008),
tumor (Liu et al., 2007), and transplanted tissues (Cobbold
et al., 2004). Our understanding of the different microenviron-
ments of iTreg cell development in vivo is still incomplete.
However, the minimal program for Foxp3+ iTreg cell develop-
ment has been defined: it requires TCR stimulation and the cyto-
kines TGF-b and IL-2, for both in vitro and in vivo generated
iTreg cells.
Addition of TGF-b to TCR-stimulated naive CD4+ T cells
induced transcription of Foxp3, acquisition of anergic and
suppressive activity in vitro, and the ability to suppress inflam-
mation in an experimental asthma model (Chen et al., 2003).
TGF-b induced Foxp3 expression in cultures of plate-bound
anti-CD3 and CD28-stimulated naive T cells (Chen et al.,
2003); thus, antigen-presenting cells (APCs) were not required
for in vitro conversion. The mechanism by which TGF-b
induces transcription of Foxp3 involves cooperation of the
transcription factors STAT3 and NFAT at a Foxp3 gene
enhancer element (Fantini et al., 2004; Josefowicz and Ruden-
sky, 2009). Consistent with the in vitro findings, in vivo neutral-
ization of TGF-b impaired oral tolerance (Faria and Weiner,
2005; Miller et al., 1992) and inhibited the differentiation of
antigen-specific Foxp3+ iTreg cells (Mucida et al., 2005).
TGF-b neutralization also blocked the iTreg cell-dependent
tolerance to male grafts in an experimental model in which
iTreg cells were induced by a nondepleting CD4 antibody
(Cobbold et al., 2004).
In contrast to the essential role of TGF-b in the differentiation
of Foxp3+ iTreg cells, the role of TGF-b in the generation of nTreg
cells is less clear. Studies with T cell-specific deletion of
TGF-bRII receptor reported that TGF-b was not involved in
thymic nTreg cell development (Fahlen et al., 2005; Li et al.,
2006; Marie et al., 2006); furthermore, young TGF-b1-deficient
mice have normal number of thymic nTreg cells. However,
a recent study offered a different interpretation, based upon
the fact that between postnatal days 3 and 5 there is a severe
deficiency in nTreg cell generation in mice that have a conditional
(lck-Cre driven) deletion of TGF-bRI (Liu et al., 2008). The
authors attributed the late surge of nTreg cells in TGF-bRI-defi-
cient mice to a heightened responsiveness of these T cells to
IL-2 and showed that double deficiency in TGF-bRI and IL-2
abrogated nTreg generation (Liu et al., 2008). Nevertheless, it
is clear that IL-2 by itself is not necessary for Foxp3+ nTreg
cell generation. We showed near normal amounts of Foxp3
mRNA in single-positive CD4+CD25+ thymocytes from young
IL-2-deficient mice, indicating that IL-2 was not required for
thymic development of Foxp3+ Treg cells (Curotto de Lafaille
et al., 2004). Two other studies used IL-2-deficient and IL-2Ra
(CD25)-deficient mice to probe the role of IL-2 in Treg cell
biology and also concluded that IL-2 was dispensable for the
generation of nTreg cells in the thymus (D’Cruz and Klein,
2005; Fontenot et al., 2005a). Finally, neutralization of IL-2 with
antibodies resulted in a strong reduction of Foxp3 expressionImmunity 30, May 22, 2009 ª2009 Elsevier Inc. 627
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guchi et al., 2005).
In the thymus of IL-2-deficient mice, the absence IL-2 is
likely to be compensated by IL-15, because CD122-deficient
mice, which have defective IL-2 and IL-15 signaling, have
a profound reduction in Treg cell development (Burchill et al.,
2007; Soper et al., 2007). Similar Treg cell defect was reported
in IL-2 and IL-15 double-deficient mice (Burchill et al., 2007).
These results are consistent with earlier work showing the
amelioration of the lymphoproliferative syndrome of CD122-
deficient mice with transgenic expression of CD122 driven by
the lck proximal promoter, a condition that restored the gener-
ation of Treg cells (Malek et al., 2002). The results are also
consistent with the expression of a constitutively active form
of STAT5B, a molecule involved in both IL-2 and IL-15 signaling
(Burchill et al., 2008). It thus appears that during development
of cells poised to become nTreg cells because of the strength
of their TCR signals, IL-2 or IL-15 can direct a TCR-indepen-
dent developmental step (Lio and Hsieh, 2008). In the
periphery, however, the role of IL-2 cannot be replaced by
IL-15.
As indicated above, IL-2 appears to be essential for iTreg cell
generation and/or homeostasis. In cultures of naive CD4+ T cells
stimulated with anti-CD3 and TGF-b, IL-2 was required to
release the TGF-b-mediated proliferation inhibition (Chen et al.,
2003). Experiments utilizing IL-2 neutralization and IL-2-deficient
T cells demonstrated that IL-2 is required in vitro for TGF-b induc-
tion of Foxp3 transcription and suppressor activity (Zheng et al.,
2007). IL-2, but not other common-g chain signaling cytokines,
could replace the requirement for CD28 costimulation for the
induction of Foxp3 by anti-CD3 and TGF-b (Davidson et al.,
2007). In vitro differentiated iTreg cells did not require IL-2 to
maintain Foxp3 expression after transfer into in RAG-deficient
recipient mice (Davidson et al., 2007). IL-2 signaling activates
STAT5. STAT5 binds to the Foxp3 gene
and may cooperate with STAT3 for
Foxp3 induction (Burchill et al., 2007; Li
and Flavell, 2008). Thus, as may be the
case for TGF-b, the requirement for IL-2
also differs between thymic-derived
nTreg cells and peripheral iTreg cells.
Another important difference between
nTreg and iTreg cell generation relates
to CTLA-4. Expression of high amounts
of Foxp3 and acquisition of suppressor
activity by naive cells activated with
TGF-b in vitro required upregulation of
CTLA-4. In contrast, CTLA-4 is not
necessary for the development of nTreg
cells in the thymus (Zheng et al., 2006).
Consistently, B7 expression in host cells
was required for the conversion of
CD4+CD25 adoptively transferred
T cells into Foxp3+CD25+ cells (Liang
et al., 2005). In contrast to CTLA-4, stim-
ulation through CD28 was shown to
inhibit TGF-b-induced Treg cell differenti-
ation in vitro (Benson et al., 2007).
However, in the thymus of CD28-defi-
cient mice, the number of nTreg cells is reduced to about one
third of the wild-type number (Salomon et al., 2000; Tai et al.,
2005).
Dendritic Cells, Retinoic Acid,
and iTreg Cell Generation in the Gut
In addition to the minimal cytokine conditions for iTreg cell devel-
opment, other microenvironmental factors may promote or
impair iTreg cell induction. Cytokines that induce the differentia-
tion of other T helper cell types (e.g., Th1, Th2, Th9, and Th17
cells) antagonize Foxp3+ Treg cell differentiation. This topic is
reviewed in this issue of Immunity by Zhou et al. (2009).
Inhibition of TGF-b-induced Treg cell development by inflam-
matory cytokines or high amount of costimulation in cell culture
could be suppressed by retinoic acid (RA) (Benson et al., 2007;
Hill et al., 2008; Mucida et al., 2007). CD103+ dendritic cells
(DCs) isolated from the small intestine and the mesenteric LN
produce both TGF-b and RA; these DCs efficiently mediate the
differentiation of naive T cells into Foxp3+ Treg cells (Coombes
et al., 2007; Sun et al., 2007). Expression of the integrin CD103
is itself regulated by TGF-b (Lim et al., 1998).
Although we know of a number of key players involved in the
induction of Foxp3+ iTreg cells in the gut and mesenteric LN,
less is known about Treg cell induction in other lymphoid organs
and tissues. CD103+ DCs, which mediate Treg cell conversion in
the gut, are abundant in the lamina propria (LP) and in the mesen-
teric LN, but are less frequent in the spleen. Recently, Yamazaki
and collaborators described CD8+DEC205+ spleen DCs that
produce TGF-b and are able to induce naive T cell differentiation
into Foxp3+ Treg cells. In contrast, CD8CD205DC inhibitory
receptor-2 (DCIR2)+ spleen DCs can induce Foxp3 expression
only if exogenous TGF-b is provided (Yamazaki et al., 2008).
The fact that CD8+CD205+ splenic DCs induce iTreg cells is
consistent with the previously described observation that628 Immunity 30, May 22, 2009 ª2009 Elsevier Inc.
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iTreg cells (Kretschmer et al., 2005).
Retinoic acid boosts the percentage of in vitro conversion into
Foxp3+ iTreg cells when TGF-b plus IL-2 is not sufficient to
promote high yield (Benson et al., 2007; Hill et al., 2008).
However, some reports show a very high frequency (more than
90%) of Foxp3+ iTreg cells without addition of RA (DiPaolo
et al., 2007). The reasons for the variation among different labo-
ratories of the frequency of Foxp3+ iTreg cells are not clear. The
main suspect is the different batches of serum, which contain
variable amounts of TGF-b and RA.
Perhaps the most compelling view of Foxp3+ iTreg cells is that
they are the result of coevolution of the adaptive immune system
and the commensal bacteria and food antigens in the gut. One
could speculate that continuous Treg cell differentiation in the
gut may be required to dampen immune reactions to gut anti-
gens. Several groups compared germ-free (GF) mice with mice
from specific pathogen-free (SPF) facilities to determine how
commensal bacteria affected the frequency and function of
Treg cells in the gut and other tissues. Because no markers
have yet been identified to differentiate nTreg from iTreg cells,
the analysis could only address the whole Treg cell population
in various tissues. The analysis of Treg cell populations in various
studies have provided discordant results, with some studies
showing a deficit in Treg cell function in GF mice (Ishikawa
et al., 2008; Ostman et al., 2006; Strauch et al., 2005) and others
showing normal numbers and function (Gad et al., 2004; Min
et al., 2007). Perhaps some of the conflicting analysis stems
from the fact that the components of the intestinal microbiota
may differ among various SPF animal facilities (Ivanov et al.,
2008). The discrepancies could also be attributed to differences
in the GF colonies (paradoxically, there are different degrees of
‘‘germ-freeness’’!), and the type of functional analysis carried
out in each case. The gut is a complex environment in which
there is induction of Th17 and Treg cells. The interplay between
Th17 and Treg cells has been widely documented and is re-
viewed in this issue by Zhou et al. (2009).
Ivanov et al. (2008) found that the proportion of Foxp3+ Treg
cells was increased in the lamina propria of the small intestine
of GF mice compared with SPF mice, whereas the proportion
of Th17 cells was greatly reduced. Interestingly, treatment of
mice for several weeks with the antibiotic vancomycin, which
reduced the population of cytophaga-flavobacter-bacteroides,
led to decrease in Th17 cells and an increase in Foxp3 Treg cells
(Ivanov et al., 2008). Similarly, Atarashi and colleagues found that
in GF mice and in mice treated with vancomycin plus metronida-
zole, Th17 cell frequency decreased in the small intestine,
whereas Treg cell frequency increased. In the LP of the large
intestine, however, Treg cell numbers also decreased in GF
mice and antibiotic-treated mice (Atarashi et al., 2008). In
summary, it appears that the microbiota impacts the Treg cell
population of animals, but it is yet unclear whether or not there
is a direct effect of the microbiota on the induction of iTreg cells.
Microrganisms activate the innate immune system through
a variety of pattern-recognition receptors (PRRs), such as the
membrane Toll-like receptors (TLR), the cytosolic nucleotide-
binding domain, and leucine-rich repeat containing (NLR) mole-
cules and RIG-I-like receptors (RLRs) (Kawai and Akira, 2009;
Palm and Medzhitov, 2009). Animals defective in selectedPRRs have been analyzed in regard to the status of their Treg
cell populations. Importantly, one must bear in mind that
a Treg cell deficiency in PRR-deficient animals does not imply
that the microbiota is exerting a direct effect on Treg cell differ-
entiation, because endogenous ligands have been described
for PRRs and, even if the microbiota is involved, it may be in
an indirect way.
Among the PRR-deficient mice that have been tested, MyD88-
and TLR2-deficient mice had reduced Treg cell numbers,
whereas TLR4-deficient mice were not affected (Sutmuller
et al., 2006; van Maren et al., 2008). In contrast, TLR9-deficient
mice had increased frequency of Foxp3+ Treg cells in intestinal
tissues and decreased frequency of IL-17- and IFN-g-producing
cells (Hall et al., 2008). Thus, PRR effects on Treg cells are
diverse and can be opposite, like the cases of TLR2 and TLR9.
It is not yet known whether natural and adaptive Treg cells are
equally affected by signaling through these receptors. In addi-
tion, local and systemic effects are likely to play a role.
Commensal bacteria are necessary to create the right gut
environment for the development of oral tolerance to food aller-
gens (Prioult and Nagler-Anderson, 2005). GF mice were less
susceptible to develop oral tolerance to OVA than were mice
reared in SPF facilities (Ishikawa et al., 2008; Moreau and Gabor-
iau-Routhiau, 1996; Rask et al., 2005; Sudo et al., 1997). TLR4-
deficient mice but not wild-type mice were highly susceptible
to food allergy (Bashir et al., 2004). Coadministration of the
TLR9 ligand CpG prevented allergy and promoted a Th1 cell
response. In summary, commensal microbiota may contribute
to the induction and/or expansion of Foxp3+ Treg cells in the
gut by directly or indirectly engaging TLR2. The inability of
TLR4-deficient mice to become tolerant to allergic sensitization
through the gut appears to be related to deficient Th1 cell induc-
tion rather than to deficient Treg cells (Bashir et al., 2004). Finally,
TLR9 engagement may affect Treg cell numbers by switching the
Treg cell-Th17 cell balance toward Th17 cell differentiation in
TGF-b-rich environments of the gut.
iTreg Cells and Infectious Tolerance
An interesting corollary of the induction of Treg cells under subim-
munogenic conditions is that Treg cells themselves contribute to
the creation of such subimmunogenic conditions. Thus, a Treg
cell-dominated environment could result in the generation of
more iTreg cells, recruited from the pool of conventional T cells.
Infectious tolerance, initially described by Gershon and Kondo
as the dominant transfer of tolerance by spleen cells from tolerant
mice to secondary recipients (Gershon and Kondo, 1971), was
later redefined by Waldmann’s laboratory. In Waldmann’s exper-
iments, transplantation tolerance was induced by short-term
treatment with nondepleting CD4 and CD8 antibodies. Adop-
tively transferred CD4+ T cells from tolerant mice not only pre-
vented transplant rejection in naive recipients but also conferred
to the recipients’ CD4 cells the ability to suppress transplant
rejection (Qin et al., 1993). Similarly, thymus epithelium induced
a population of regulatory T cells that, upon transfer into a
secondary recipient, was able to recruit recipient-derived
T cells into a tolerance-inducing function (Modigliani et al.,
1996). Mechanistically, activated Foxp3+ Treg cells, but not
resting Treg cells, expressed TGF-b coupled to latency-associ-
ated peptide LAP. Activated Treg cells induced the differentiationImmunity 30, May 22, 2009 ª2009 Elsevier Inc. 629
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contact-dependent manner (Andersson et al., 2008).
Given these facts, it is unclear why infectious tolerance mech-
anisms do not recruit a larger fraction of the conventional T cell
pool into the iTreg cell compartment. For example, in a myelin
basic protein (MBP)-specific TCR transgenic system lacking
nTreg cells, transfer of polyclonal nTreg cells could prevent the
development of spontaneous autoimmune encephalomyelitis
(EAE), but even as these nTreg cells are at work protecting the
recipients from EAE, they do not transfer their regulatory function
to recipients’ MBP-specific T cells. Antibody-mediated elimina-
tion of the transferred nTreg cells resulted in the rapid onset of
EAE, indicating that nTreg cell-induced conversion of MBP-
specific Treg cells into Foxp3+ iTreg cells did not take place or
was minimal (Hori et al., 2002). It is thus apparent that infectious
tolerance operates under a set of special conditions that go
beyond the creation of subimmunogenic conditions.
There is no doubt that we still have an incomplete under-
standing on the different conditions that lead to iTreg cell differ-
entiation in vivo, the inductive microenvironments, the APCs that
are involved, and the neutralization of specific inhibitory factors.
Differences between nTreg and Foxp3+ iTreg Cells
A number of studies have provided data that shed light on the
differences between nTreg and iTreg cells as well as the differ-
ences between iTreg cells generated in different ways. Within
iTreg cells, the differences between in vitro and in vivo generated
iTreg cells are not fully understood. There has been some
disagreement on whether in vitro generated Foxp3+ iTreg cells
are as good suppressor cells as natural Treg cells (Aricha
et al., 2008; Chen et al., 2003; DiPaolo et al., 2007; Hill et al.,
2007; Horwitz et al., 2008; Selvaraj and Geiger, 2008), but there
is consensus that in vivo generated iTreg cells are effective
suppressors (Apostolou and von Boehmer, 2004; Cobbold
et al., 2004; Curotto de Lafaille et al., 2008; Knoechel et al.,
2005; Mucida et al., 2005).
Studies on methylation of CpG motifs in the Foxp3 locus of
natural Foxp3+ Treg cells identified complete demethylation
within an evolutionary conserved region upstream of exon 1,
named TSDR (Treg cell-specific demethylated region). TSDR de-
methylation is unique to Foxp3+ regulatory T cells. In contrast to
nTreg cells, in vitro generated iTreg cells displayed only partial
demethylation in spite of high Foxp3 expression. These in vitro
generated iTreg cells, but not nTreg cells, lost both Foxp3
expression and suppressive activity when restimulated in the
absence of TGF-b (Floess et al., 2007; Huehn et al., 2009). A
marked difference in the methylation state of TSDR between
in vitro and in vivo generated iTreg cells has been reported.
Like nTreg cells, but unlike in vitro generated iTreg cells, iTreg
cells generated in vivo by administration of antigen coupled
with DEC205 antibodies displayed efficient TSDR demethylation
(Polansky et al., 2008). A potential problem that needs to be
addressed in future studies is the timing of TSDR demethylation.
Although in vitro generated iTreg cells were analyzed for TSDR
demethylation only 6 days after induction with TGF-b (Floess
et al., 2007), the in vivo generated iTreg cells were analyzed
3 weeks after administration of antigen (Polansky et al., 2008).
These differences in the time of analysis could be significant.
Consistent with this view, Floess et al. (2007) showed that in630 Immunity 30, May 22, 2009 ª2009 Elsevier Inc.the thymus, TSDR demethylation in CD4+SP Foxp3+ nTreg cells
is not yet complete. Thus it may take some time before TSDR
demethylation is completed in both iTreg and nTreg cells.
Gene profiling studies have defined a subset of genes ex-
pressed in natural Foxp3+ Treg cells defined as the Treg cell
signature. Part of the Treg cell signature corresponds to genes
that are induced or repressed in Treg cells independently of
Foxp3 expression, with the other gene subset being downstream
of Foxp3. Hill et al. (2007) compared the expression of the Treg
cell signature genes in Treg cells generated in a number of
different conditions, including in vitro generated iTreg cells. Of
relevance to the discussion here, the authors found that in vitro
generated Foxp3+ iTreg cells lacked part of the Treg cell signa-
ture genes, despite their high expression of Foxp3 (Hill et al.,
2007). A caveat of the analysis is that the iTreg cells analyzed in
the above study displayed poor suppression activity in vitro
and in vivo. Further comparison of in vitro generated Foxp3+ iTreg
and nTreg cell by expression microarray was recently
reported (Haribhai et al., 2009). However, the gene expression
profile of in vivo generated iTreg cells has not yet been reported.
Furthermore, there are no consensus nTreg and iTreg cells
markers that can be used to study the properties of each type
separately.
Foxp3+ iTreg cells, by definition, have the TCR repertoire of
naive conventional T cells. This conventional TCR repertoire is
different from Foxp3+ Treg cells (Hsieh et al., 2004, 2006; Pa-
cholczyk et al., 2006; Wong et al., 2007b). An overlap between
the two TCR repertoires has been highlighted in all reports,
although there was variation among the studies regarding the
similarity index, calculated as lower than 25% (Hsieh et al.,
2004), between 10% and 20% (Pacholczyk et al., 2006), or
42% (Wong et al., 2007b). The repertoire overlap could be
explained by the presence of iTreg cells, which will have
a conventional T cell repertoire but will be analyzed in the
Foxp3+ group mixed with nTreg cells. The repertoire overlap
could also be interpreted as indicating that, although TCR
signaling is important in determining the commitment along the
Foxp3+ pathway, other factors are also important, or that there
is a stochastic component to Treg cell selection.
A more recent study indicated that even though a relatively
high percentage of the TCR sequences from conventional
T cells were found in Treg cells and, likewise, a high percentage
of the TCR sequences from Treg cells were found in the conven-
tional T cells, the frequency of these ‘‘shared’’ sequences in the
two T cell populations was dramatically different (Pacholczyk
et al., 2007). Overall, the studies point to the fact that the reper-
toire of Treg cells and conventional T cells is different. As indi-
cated above, it is tempting to speculate that the Treg cell TCR
sequences shared with conventional T cells correspond to iTreg
cells. In fact, because the repertoire overlap between Treg cells
and conventional T cells was small, this could be interpreted as
indicating that the contribution of iTreg cells to the total Treg cell
pool is small. If the frequency of iTreg cells among total Treg
cells were high, the repertoires of conventional T cells and
Treg cells would be more overlapping. One problem with this
conclusion is that it is based upon nonimmunized mice housed
under clean, specific-pathogen-free conditions. As discussed
below in this review, it has become apparent that chronic anti-
genic exposure represents one of the main sources of iTreg
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sure to infections and antigenic stimulation would also have
a limited iTreg cell contribution. Some of the established differ-
ences between Foxp3+ nTreg and iTreg cells are summarized in
Box 1.
iTreg Cells in Mucosal Tolerance
and Chronic Inflammatory Responses
Mucosal tolerance to environmental and food antigens is essen-
tial to prevent exacerbated immune reactions that can cause
allergic diseases and chronic inflammation, and it has long being
recognized that the gut is an important site for the induction of
tolerance (Faria and Weiner, 2005). Currently, there is no exper-
imental system that allows the study of nTreg cells in the
absence of iTreg cells, because every Foxp3+ population is likely
to contain an iTreg cell component. However, the converse study
is possible. TCR transgenic RAG-deficient mice have mono-
clonal T cell repertoires and were shown to lack nTreg cells
initially through their enhanced susceptibility to spontaneous
autoimmune disease (Lafaille et al., 1994). When Foxp3 staining
became available, it was confirmed that these mice lack Foxp3+
T cells (Kretschmer et al., 2005; Shen et al., 2005). The lack of
nTreg cells in TCR transgenic RAG-deficient mice is consistent
with the accepted models of high-affinity thymic selection of
nTreg cells (i.e., the transgene-encoded T cell receptors do not
encounter the appropriate high-affinity ligand in the thymus),
although there are alternative explanations. In TCR transgenic
RAG-deficient mice, iTreg cells can be generated, as described
above, in the absence of nTreg cells. By using one such experi-
mental system (T-Bmc) in which the T cells recognize OVA, we
determined that administration of OVA in the drinking water led
to generation of OVA-specific Foxp3+ iTreg cells (Mucida et al.,
2005). These cells were responsible for oral tolerance, because
crossing of the T-Bmc mice with Foxp3-deficient mice abro-
gated oral tolerance, even though other tolerance mechanisms
were intact in these mice (Curotto de Lafaille et al., 2008). In spite
of being deficient in nTreg cells and unable to generate Foxp3+
iTreg cells, Foxp3-deficient T-Bmc mice are healthy throughout
life if antigen is not administered, because all T and B cells recog-
nize foreign antigens.
OVA-specific iTreg cells were also induced in wild-type mice
with polyclonal repertoires of conventional T and Treg cells, via
bone marrow reconstitution of BALB/c mice with a small propor-
tion of OVA-specific T cell progenitors (Curotto de Lafaille et al.,
2008). Thus, in the absence of nTreg cells, induction of Foxp3+
iTreg cells is essential to establish tolerance and avoid allergic
sensitization.
In the same mouse system, OVA-specific iTreg cells were also
induced by immunization with OVA in alum, a protocol used to
induce experimental allergic asthma. In this case, however,
Foxp3+ iTreg cells were generated concomitantly with a much
more robust effector Th2 cell response. These immunization-
induced iTreg cells did not prevent the primary IgE response
and acute eosinophilic inflammation in the lung. However, iTreg
cell numbers rapidly built up in the lungs of immunized mice after
airway challenge and became prominent after repeated antigen
exposure. In a chronic model of allergic inflammation, iTreg
cells, in the absence of nTreg cells, were essential to reduce
the severe inflammation and lung remodeling, suppressneolymphoid development in the lung, and prevent the dissem-
ination of Th2 cells to distant LN and the skin (Curotto de
Lafaille et al., 2008). Thus, in tolerogenic conditions, antigen-
specific Foxp3+ Treg cells are induced but Th effector cells are
not. These Treg cells efficiently block the development of
effector Th cells and prevent inflammation upon subsequent
immunization. In contrast, immunization-induced Treg cells
that develop concomitant with effector T cells do not prevent
acute inflammation but expand on inflammation. They function
to suppress severe inflammation and the spreading of Th cell
effectors to distant LN and tissues.
Treg Cells and Infections
With few exceptions, chronic infectionshavebeen associatedwith
increased Foxp3+ Treg cell numbers. Induction and/or expansion
of Treg cells during infections could be responsible for a failure to
clear the infection, with consequent establishment of a chronic
phase in which Treg cells are involved in limiting immune-medi-
ated tissue damage. The role of Treg cells during infections has
been recently reviewed (Demengeot et al., 2006; Wohlfert and Bel-
kaid, 2008). The presence of Treg cells during infections is an
important barrier for vaccination and treatment strategies. Impor-
tant for the purpose of this review, the accumulation of Foxp3+
Treg cells during infections could be due to expansion of nTreg
cells and/or to conversion of naive T cells to iTreg cells.
Many parasites establish persistent infections in the mamma-
lian host that modulate the immune system in ways that allow
long-term parasite survival (Wohlfert and Belkaid, 2008). An
increase in the Foxp3+ Treg cell population was demonstrated
in several models of rodent filariasis (Maizels, 2007; McSorley
et al., 2008). Interestingly, Brugia malayi secretes a homolog of
mammalian TGF-b (Gomez-Escobar et al., 2000) that may be
involved in Treg cell conversion. Further, increased Foxp3+
Treg cells and IL-10-producing Tr1 cells may be responsible
for the lower incidence of allergic disease in individuals infected
with helminth parasites (Wills-Karp et al., 2001; Wilson and Mai-
zels, 2004). Expansion of pathogen-specific Foxp3+ Treg cells
was also observed in bacterial infections, such as Listeria mono-
cytogenes (Ertelt et al., 2009). Helicobacter pylori establish
chronic infections that can be cured by antibiotic treatment.
However, cured individuals are not immune to reinfection. A
large increase in transcripts for Foxp3 and TGF-b was found in
the gastric mucosa of H. pylori-infected individuals (Kandulski
et al., 2008). Interestingly, memory peripheral blood T cells
from infected and uninfected individuals proliferated to H. pylori
antigens, but only in infected individuals did the depletion of Treg
cells lead to enhanced proliferation, suggesting the existence of
H. pylori-specific Treg cells (Lundgren et al., 2003).
In addition to parasitic and bacterial infections, chronic viral
infections have been described with enhanced Treg cell activity
(reviewed by Robertson and Hasenkrug, 2006). The involvement
of Treg cells may be particularly important to investigate in
chronic viral infections for which there are no vaccines and no
cure, such as HIV and hepatitis C virus (HCV) (Alatrakchi and
Koziel, 2009; Dolganiuc and Szabo, 2008; Li et al., 2008). HCV
infection is the most common blood-borne infection in the USA.
Chronic infections are associated with a weak virus-immune
response, impaired DC function (Li et al., 2008), and increased
Foxp3+ Treg cells (Ebinuma et al., 2008; Ward et al., 2007). InImmunity 30, May 22, 2009 ª2009 Elsevier Inc. 631
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indicates that it is possible to mount effective immunity. Clearly,
induction of iTreg cells can be an impediment to successful
vaccination. More needs to be known about the type of response
that leads to resolution of infection and effective immunity.
iTreg Cells and Cancer
It has become evident that Foxp3+ Treg cells are one of the main if
not themain barrier to the implementation of cancer immuno ther-
apies (Curiel, 2008; Zou, 2006). Elimination of Treg cell function
with CD25 antibodies resulted in survival of experimental animals
that otherwise would succumb to cancer (Onizuka et al., 1999;
Shimizu et al., 1999). Tumor tissues promote the conversion of
naive T cells into Foxp3+ Treg cells and the accumulation of
Treg cells in tumor sites, thereby impairing the development of
effector responses (Liu et al., 2007; Nishikawa et al., 2003).
Thus, Foxp3+ iTreg cells have a key function in obstructing tumor
immunosurveillance (Liu et al., 2007; Zhou and Levitsky, 2007).
Absence of iTreg Cell Generation
In some experimental conditions where generation of iTreg cells
would have been expected, investigators reported lack of conver-
sion of naive polyclonal or antigen-specific CD4+ T cells into
Foxp3+ Treg cells. For example, when CD4+CD25RFP(Foxp3)
cells were transferred into RAG-deficient mice, the animals devel-
oped inflammatory bowel disease (IBD) with no conversion of
transferred cells to RFP+(Foxp3+) Treg cells during 6 weeks of
observation (Wan and Flavell, 2005). In addition, at least two
reports failed to identify substantial iTreg cell generation during
infections. In mice infected with OVA-expressing Listeria mono-
cytogenes, OVA-specific naive T cells expanded but did not
convert to Foxp3+ (Fontenot et al., 2005b). Similarly, the Treg cells
accumulated in lymph nodes that drain Leishmania-infected
tissues were derived from a population of CD4+CD25+ Treg cells,
and not from cotransferred CD4+CD25 T cells (Suffia et al.,
2006).
There are also examples of lack of conversion in experimental
autoimmunitysystems. When total CD4+ T cellsorFoxp3-negative
T cells from Foxp3-GFP reporter mice were injected into MOG-
immunized mice, GFP+ Treg cells accumulated in the central
nervous system only when total cells but not when GFP-negative
cells were injected, thus attributing the accumulation of Foxp3+
T cells to expansion of nTreg cells (Korn et al., 2007). Finally, by
using a TCR transgenic system, BDC2.5, that recognized
a pancreatic antigen, Wong et al. (2007a) compared the endoge-
nous TCRa chain sequences expressed by Foxp3 and Foxp3+
T cells and found signature CDR3 TCRa sequences. Comparison
of these signature sequences in the thymus and periphery indi-
cated that exposure to the pancreatic self-antigen in the periphery
did not cause the signature Foxp3 sequences to appear in the
Foxp3+ compartment. The authors proposed that little or no
peripheral conversion of Foxp3 into Foxp3+ cells occurred
upon encounter with antigen in this model (Wong et al., 2007a).
In some cases, it is possible to speculate that the lack of
detection of Foxp3+ iTreg cells was due to low sensitivity of the
readouts, or to potential expression of the antigen in the thymus
(in the case of the BDC2.5 experiment), or even to iTreg cells
present in the original CD25+ cell transfer (in the case of the
Leishmania experiment). However, it is very unlikely that such632 Immunity 30, May 22, 2009 ª2009 Elsevier Inc.technical problems would affect all the experiments described
above. Much more likely is that there was little or no iTreg cell
generation, reflecting the fact that we do not know the full assort-
ment of conditions that result in iTreg cell generation or lack
thereof, and how this process is regulated by tissue environ-
ment, antigen specificity, and pre-existing Treg cells.
Synergistic Functions for nTreg Cells and iTreg Cells
A consensus exists for the role of nTreg cells in preventing auto-
immunity and preventing exaggerated immune responses.
Experimental data now support the importance of Foxp3+ iTreg
cells in mucosal tolerance and in inflammatory responses to
foreign antigens, in the suppression of responses to neo-antigens
in tumors and transplants. However, the extent of the contribution
of iTreg and nTreg cells in normal animals has been difficult to
evaluate because of the lack of suitable surface markers or
reporter mice distinguishing iTreg and nTreg cell populations.
The interplay between nTreg cells and iTreg cells in different
immune responses is beginning to be addressed. Haribhai and
colleagues used a transfer model of colitis to compare the func-
tion of nTreg cells, in vitro induced iTreg cells, and in vivo induced
iTreg cells (Haribhai et al., 2009). As expected, transfer of naive
Foxp3CD4+ cells into RAG-deficient mice induced colitis. If
the naive T cells were unable to become iTreg cells in vivo
because of a Foxp3 mutation, the disease progressed faster,
indicating that in vivo differentiated Treg cells conferred some
protection, although the specificities of the effector T cells could
be different in Foxp3-sufficient and -deficient mice (Hsieh et al.,
2006). nTreg cells were better at controlling disease than
in vitro induced iTreg cells when transferred into mice that had
received naive cells capable of generating in vivo iTreg cells
(i.e., from Foxp3-sufficient donors), but, importantly, only the
combination of nTreg and in vitro generated iTreg cells could
protect mice that had received naive cells that were unable to
generate in vivo iTreg cells (i.e., from Foxp3-deficient donors). If
the naive T cell population had derived from mice that could
generate in vivo iTreg cells, then full protection from colitis could
be afforded by nTreg cells alone. Thus, in this colitis model, both
natural and induced (in vitro induced or in situ induced) Treg cells
were required for protection from disease. One must add that in
this and most other cases, the nTreg cell population is, in reality,
a total population containing a majority of nTreg cells and some
in vivo generated iTreg cells. Because these Treg cells originate
from clean, nonimmunized animals, the contribution of iTreg cells
to the total Foxp3+ Treg cell pool is likely to be small, as indicated
by the TCR repertoire analysis discussed above.
Altogether, the results discussed above indicate a similarity of
function between iTreg cells generated in vitro and in vivo. Of
relevance, a divergence of function between nTreg cells and
iTreg cells in the regulation of the same disease was uncovered.
Thus, it is possible that in many instances, nTreg and iTreg cells
synergize to achieve optimal regulation. It is quite likely that there
is a division of labor between nTreg cells and iTreg cells, some-
thing that could have been predicted based upon the different
TCR repertoires of both Treg cell populations (Figure 1).
Concluding Remarks
Although their existence was controversial for some time, it is
now absolutely clear that iTreg cells develop under a variety of
Immunity
Reviewconditions, quite possibly during the normal homeostasis of the
gut (Box 1). For what we know at this time, iTreg cells play essen-
tial roles in immune tolerance and in the control of severe chronic
allergic inflammation, are responsible for preventing the clear-
ance of parasites and other microorganisms, and are one of
the main barriers to the immune eradication of tumors. Although
iTreg cells seem tailored to respond to foreign antigens and neo-
antigens (such as tumor antigens), it is likely that they are also
generated in response to self-antigens and synergize with nTreg
cells in the control of autoimmune inflammation.
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